Skip to main content
Caplight Logo









BioFluidica

BioFluidica

Private
Lawrence, KansasHealthcare & Life Scienceshttps://www.biofluidica.com/

Last Round

Series B

Extension

Feb 8, 2022

Total Funding Raised

$15.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BioFluidica is a biotechnology company that provides a liquid biopsy platform for the isolation and analysis of rare cells, extracellular vesicles, and cfDNA.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Services & Consulting

AI Layer

Non-AI

Keywords

liquid biopsymicrofluidicscirculating tumor cellsCTCexosome isolationbiomarker enrichmentlab automationprecision medicineprenatal diagnosticsliquid handlingbiotech equipmentsingle-cell analysissample processingliquid biopsy techlab-on-a-chip

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioFluidica Comparables

Compare BioFluidica with similar companies based on industry and business-model similarity.

BioFluidica comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vortex Biosciences
83%
Creatv MicroTech, Inc.
81%
Cytotrait
80%

BioFluidica Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 8, 2022
GrantAug 12, 2021
GrantJan 10, 2019
GrantJan 7, 2019
Series BJul 21, 2017
Series A
Apr 4, 2016

Key People

Founding team and executive leadership

Greg Studdard

Chief Executive Officer

Executive Team

BioFluidica Investors

Notable investors and investment history

BioFluidica investors
InvestorRounds
National Cancer InstituteGrant
National Institutes of Health (NIH)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 37% MoM, reaching 1.8K.

  • May 12, 2026

    Monthly visitors increased 334% MoM, reaching 2K.

BioFluidica Filings

Explore SEC and related filing metadata, where available.

BioFluidica filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BioFluidica's valuation, stock price, and market status.

Is BioFluidica a public or private company?

BioFluidica is a private company.

What is the current stock price of BioFluidica?

BioFluidica is a private company with no public stock price. No recent secondary market data is available.

How much is BioFluidica worth (valuation)?

Valuation information for BioFluidica is not publicly available.

Can I buy BioFluidica stock?

BioFluidica shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BioFluidica's last funding round?

BioFluidica's most recent funding round was Series B Extension on February 8, 2022.

Who are the main investors in BioFluidica?

Key investors in BioFluidica include National Cancer Institute, National Institutes of Health (NIH).

Will BioFluidica IPO soon?

No public IPO plans have been announced for BioFluidica.

How can I track BioFluidica secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BioFluidica's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLawrence, Kansas
Employee Range8
Year Founded2006
Last FundingFeb 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?